About this course
Osteoporosis is a disorder of the bone characterized by a reduction bone density due to the depletion of structural components, especially calcium and bone protein.
Older adults, including but not limited to postmenopausal women and men receiving androgen-deprivation therapy, are particularly prone to osteoporotic skeletal malformations and fractures. Although none of the currently available drugs can provide cure, evidence show that pharmacologic interventions provide significant therapeutic benefits for patients at risk of osteoporosis.
Considering the substantial socio-economic burden associated with this chronic disease, an effective and pragmatic approach for its long-term management is important.
This lecture discusses the various therapeutic options for osteoporosis, with emphasis on denosumab, a first-line anti-osteoporotic drug with a novel mechanism of action.
1 CME Point Available (Category 3A)
- Complete the videos and quiz to qualify for 1 CME Point (Category 3A).
- A certificate will be provided upon successful completion. Please use the information on the certificate to claim your points via SMC website.
- Doctors who have attended the face-to-face meeting will not be eligible for additional CME points for completing this module.
- Prof. Michael R. McClung, MD, FACP
- Professorial Fellow, Institute for Health and Ageing
- Australian Catholic University, Melbourne, VIC
- Director, Oregon Osteoporosis Center
- Portland, Oregon, USA
Prof. Michael R. McClung is a specialist in endocrinology and internal medicine. He is an internationally recognized expert educator and clinical researcher in the field of osteoporosis and bone density.
Prof. McClung is sits on the editorial board for numerous bone journals has published over 150 peer-reviewed articles. He is also an active board member of the International Osteoporosis Foundation and the North American Menopause Society.
An educational talk supported by Amgen